Milford, Mass. - 2012-04-05
for larger version)
At a ceremony on March 27, Waters honored Prof. Pauline
Rudd for her pioneering research in glycobiology. Pictured
are (from left to right) Mike Harrington, Ph.D., Vice
President, European and Asia Pacific Operations, Waters
Division, Prof. Pauline Rudd, and Minister Sean Sherlock
TD, Irish Minister for Research and Innovation, Department
of Jobs, Enterprise & Innovation.
At a ceremony officiated by Minister Sean Sherlock TD,
Irish Minister for Research and Innovation, Department of
Jobs, Enterprise & Innovation, Waters Corporation (NYSE:WAT)
welcomed the Irish National
Institute for Bioprocessing Research and Training
(NIBRT) into its Centers
of Innovation Program. Waters acknowledged NIBRT and
the research team under the direction of Prof.
Pauline Rudd, Principal Investigator, for her
pioneering contribution to the field of glycobiology, a
science of growing importance to both biotherapeutics
manufacturers and disease research.
"I am honored to be a part of the Centers of Innovation
Program and for what it means to us as we conduct
leading-edge research. I regard Waters as more than just an
instrument vendor; they are a research partner," said Prof.
Prof. Rudd and her team are working with Waters® mass
spectrometry based systems to take challenging glycan
characterization to the next level. By improving
understanding of glycan chemical and molecular structure,
scientists can better understand safety and efficacy
profiles for a potential molecule, leading directly to
novel biotherapeutic options.
"It's truly exciting to announce and confirm our
collaboration with Pauline and NIBRT," said Mike
Harrington, PhD, Vice President European and Asia Pacific
Operations, Waters Division. "At Waters we believe in the
science of what's possible, that there are no problems that
science cannot solve. We're lucky to be working with a
dedicated partner like NIBRT which believes in the power of
science and the importance of research and training.
Biopharmaceuticals are increasingly important to patients
and drug manufacturers. By 2014, it is expected that 50% of
the top 100 prescribed medications will be
biopharmaceuticals, including four of the top five selling
drugs. Ireland's exports of pharmaceuticals valued at
approximately $55 billion Euros now accounts for more than
50% of the country's GDP.
"In the future most new pharmaceuticals coming on line will
be glycoproteins, very large and complex molecules and very
challenging to analyze to ensure their safety and efficacy.
We're now moving to a new phase of technical development
not only for glycan analysis but for full product
characterization. So these wonderful instruments from
Waters will help us move the field forward and train the
next generation of scientists in glycobiology," Prof. Rudd
In other news, Waters and NIBRT have established the
Complete Product and Processing Characterization Facility
(CPPCF) for hands-on laboratory based scientific training
and retraining of 'fit-for-purpose' biopharmaceutical
analysis, including protein and peptide characterization.
The CPPCF's goal is to provide comprehensive training of
industry and governmental technicians and scientists to
help the burgeoning industry develop advanced
biotherapeutic characterization. The new facility will also
educate scientists on existing and upcoming U.S. and
European drug regulations.
"The combination of Pauline Rudd's expertise in
glycan analysis and Waters technology for analysis of
complex biological samples provides a unique combination of
capabilities that can help underpin Ireland's continued
reputation as a centre of excellence for the very highest
quality standards in biopharmaceutical manufacturing,"
commented Minister Sherlock. "I'm truly delighted to
announce this collaboration as it will surely assist both
NIBRT and Waters in further cementing their reputation as
providers of choice for the biopharmaceutical industry and
Ireland's reputation as a world leading location for
biotech manufacturing." He added, "It's a privilege for me
to acknowledge this collaboration, to congratulate Pauline
and to see that the collaboration between NIBRT and Waters
continues to flourish."
Waters is the leader in biopharmaceutical analytical
technology, which is fundamental to the advancement of
biopharmaceuticals. The company offers a comprehensive
technology solution that gives biopharmaceutical
manufacturers the analytics they need from discovery to
development to commercialization and everything in between.
Waters' effort with NIBRT is the latest demonstration of
the company's commitment to creating partnerships that
enable it to multiply its impact on critical public health
issues, including food safety, safe drugs and clean water.
About Waters Centers of Innovation Program
Centers of Innovation Program recognizes and supports
the efforts of scientists facilitating breakthroughs in
health and life science research, food safety,
environmental protection, sports medicine and many other
Prof. Rudd joins 19 others researchers and research centers
recognized by Waters' Centers of Innovation Program.
The others include Professor
Jeremy Nicholson, Imperial College London; Professor
John Engen, Northeastern University, Boston, Mass.; Professor
James Scrivens, University of Warwick, Coventry, UK; Professor
David Cowan of Kings College London; Professor
Arthur Moseley of Duke University, Durham, North
Julie Leary of the University of California - Davis;
Albert J. Fornace, Jr., Georgetown Lombardi
Comprehensive Cancer Center, Washington, D.C.; Professor
Marcos Eberlin, University of Campinas, Brazil; Dr.
Chang Hsu, Future Fuels Institute, Tallahassee,
Ganesh Anand, National University of Singapore; Dr.
Konstantinos Petritis, Translational Genomics Research
Institute, Phoenix, Arizona; Professor Vladimir Shulaev, University of North Texas
Department of Biological Sciences, Denton, Texas; Dr.
Joseph Dalluge, University of Minnesota: Prof. Sarah
Trimpin, Wayne State University; Dr.
Frank Gonzalez, National Cancer Institute; Dr.
Devin Peterson, University of Minnesota, Caroline West
and Eric Lesselier, Universite d'Orleans; and
Burt van Bavel, Orebro University.
These leading scientists, in partnership with Waters, are
using liquid chromatography and mass spectrometry to take
research down new paths and help unlock the mysteries of
The National Institute for Bioprocessing Research and
Training, Dublin, Ireland is a centre of excellence that
supports the biopharma sector by offering research platform
solutions for bio-manufacturing and provides tailored
accredited industrial training and academic educational
programmes to students in purpose-built flexible and modern
bioprocessing facilities that will facilitate the expansion
of the biopharma sector in Ireland. For further
information, please refer to www.nibrt.ie.
For over 50 years, Waters Corporation (NYSE:WAT) has
created business advantages for laboratory-dependent
organizations by delivering practical and sustainable
innovation to enable significant advancements in such areas
as healthcare delivery, environmental management, food
safety, and water quality worldwide.
Pioneering a connected portfolio of separations science,
laboratory information management, mass spectrometry and
thermal analysis, Waters technology breakthroughs and
laboratory solutions provide an enduring platform for
With revenue of $1.85 billion in 2011, Waters is driving
scientific discovery and operational excellence for